Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Krystal Biotech (NASDAQ:KRYS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Valuation and Earnings
This table compares Revolution Medicines and Krystal Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $11.58 million | 3,218.01 | -$1.13 billion | ($9.11) | -18.91 |
| Krystal Biotech | $470.02 million | 19.24 | $204.83 million | $7.37 | 41.42 |
Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Revolution Medicines has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Revolution Medicines and Krystal Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 1 | 1 | 21 | 1 | 2.92 |
| Krystal Biotech | 1 | 1 | 10 | 2 | 2.93 |
Revolution Medicines currently has a consensus price target of $262.75, suggesting a potential upside of 52.50%. Krystal Biotech has a consensus price target of $375.00, suggesting a potential upside of 22.86%. Given Revolution Medicines’ higher probable upside, equities analysts clearly believe Revolution Medicines is more favorable than Krystal Biotech.
Profitability
This table compares Revolution Medicines and Krystal Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -84.51% | -51.97% |
| Krystal Biotech | 47.91% | 17.02% | 15.48% |
Summary
Krystal Biotech beats Revolution Medicines on 10 of the 15 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
About Krystal Biotech
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
